1 – 6 of 6
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2016
-
Mark
Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer
(
- Contribution to journal › Article
- 2015
-
Mark
Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications.
(
- Contribution to journal › Article
-
Mark
PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer
(
- Contribution to journal › Article
- 2013
-
Mark
mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer
(
- Contribution to journal › Article
- 2008
-
Mark
Models from experiments: combinatorial drug perturbations of cancer cells
(
- Contribution to journal › Article
- 2007
-
Mark
Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity
(
- Contribution to journal › Article